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BIOSYNTHETIC GENES AND HOST CELLS 
FOR THE SYNTHESIS OF POLYKETIDE 
ANTIBIOTICS AND METHOD OF USE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is the US. national stage application of 
International Patent Application No. PCT/US2003/33142 
?led Oct. 17, 2003, Which claims the bene?t of US. Provi 
sional patent application With Ser. No. 60/419,463, ?led Oct. 
18, 2002 the disclosures of Which are hereby incorporated by 
reference in their entirety, including all nucleic acid 
sequences, amino acid sequences, chemical formulae, tables 
and ?gures. 
TECHNICAL FIELD 
The Sequence Listing for this application is labeled “seq 
list-replace.txt” Which Was created on Jun. 26, 2008 and is 
323 KB. The entire contents of the sequence listing is incor 
porated herein by reference in its entirety. 
The invention is in the ?eld of genetic engineering, and in 
particular the isolation and expression of the biosynthetic 
genes that produce a family of antibiotics knoWn generically 
as albicidins. 
BACKGROUND OF THE INVENTION 
US. Pat. No. 4,525,354 to Birch and Patil described a 
“non-peptide” antibiotic of M.W. “about 842” called “albici 
din.” Albicidin is described as produced by culturing chloro 
sis-inducing strains of Xanlhomonas albilineans isolated 
from diseased sugarcane, and mutants thereof. The antibiotic 
Was isolated from the culture medium by adsorption on resin 
and Was puri?ed by gel ?ltration and High Performance Liq 
uid Chromatography (HPLC). The chemical structure of this 
antibiotic Was not determined and remained unknown, 
although the Birch and Patil patent disclosed spectral data for 
a fraction having antibiotic activity and the presence of 
approximately 38 carbon atoms and at least one COOH 
group. 
Xanlhomonas albilineans is a systemic, xylem-invading 
pathogen that causes leaf scald disease of sugarcane (inter 
speci?c hybrids of Saccharum species) (Ricaud and Ryan, 
1989; Rott and Davis, 2000). Leaf scald symptoms include 
chlorosis, necrosis, rapid Wilting, and plant death. Chlorosis 
inducing strains of the pathogen produce several toxic com 
pounds. The major toxic component, named albicidin, inhib 
its chloroplast DNA replication, resulting in blocked 
chloroplast differentiation and chlorotic leaf streaks that are 
characteristic of the plant disease (Birch and Patil, 1983, 
1985b, 1987a and 1987b). Several studies established that 
albicidin plays a key role in pathogenesis and especially in the 
development of disease symptoms (Wall and Birch, 1997; 
Zhang and Birch, 1997; Zhang et al., 1999; Birch, 2001). 
The prior art indicates that albicidin inhibits prokaryotic 
DNA replication and is bactericidal to a range of gram-posi 
tive and gram-negative bacteria (Birch and Patil, 1985a). 
Albicidin is therefore of interest as a potential clinical anti 
biotic (Birch and Patil, 1985a). HoWever, loW yield of toxin 
production inX albilineans has sloWed doWn studies into the 
chemical structure of albicidin and its therapeutic application 
(Zhang et al., 1998). The chemical structure of this albicidin 
remains unknown, hoWever this albicidin has been partially 
characterized as a non-peptide antibiotic With a molecular 
Weight of about 842 that contains approximately 38 carbon 
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atoms With three or four aromatic rings, at least one COOH 
group, tWo OCH3 groups, a trisubstituted double bond and a 
CN linkage (Birch and Patil, 1985a; Huang et al., 2001). 
Molecular cloning and characterization of the genes gov 
eming the biosynthesis of albicidin is of considerable interest 
because such information provides approaches to engineer 
overproduction of albicidin, to characterize its chemical 
structure, to alloW therapeutic applications and to clarify the 
relationship betWeen toxin production and the ability to colo 
nize sugarcane. TWo similar mutagenesis and complementa 
tion studies have been conducted to identify the genetic basis 
of albicidin production in X albilineans strains isolated in 
tWo different geographical locations, Australia and Florida. 
One study of X albilineans strain LS155 from Australia 
revealed that genes for albicidin biosynthesis and resistance 
span at least 69 kb (Wall and Birch, 1997). Subsequently, 
three genes required for albicidin biosynthesis Were identi 
?ed, cloned and sequenced from tWo Australian strains of X 
albilineans (LS155 and Xa13): xabA, xabB and xabC (Huang 
et al., 2001; Huang et al. 2000a, 2000b). The xabB gene 
encodes a large protein With a predicted size of 525.6 kDa, 
With a modular architecture indicative of a multi functional 
polyketide synthase (PKS) linked to a nonribosomal peptide 
synthetase (NRPS) (Huang et al., 2001). The xabC gene, 
located immediately doWnstream from xabB, encodes an 
S-adeno syl-L-methionine (SAM)-dependent O-methyltrans 
ferase (Huang et al., 2000a). The xabA gene, located in 
another region of the genome, encodes a phosphopantethei 
nyl transferase required for post-translational activation of 
PKS and NRPS enzymes (Huang et al., 2000b). 
These ?rst results demonstrated that the albicidin biosyn 
thesis apparatus is a PKS and/ or NRPS system. Such systems 
assemble simple acyl-coenzyme A or amino acid monomers 
to produce polyketides and/or nonribosomal peptides (Ma 
rahiel et al., 1997; Cane, 1997; Cane and Walsh, 1999). These 
metabolites form very large classes of natural products that 
include numerous important pharmaceuticals, agrochemi 
cals, and veterinary agents such as antibiotics, immunosup 
pressants, anti-cholesterolemics, as Well as antitumor, anti 
fungal and antiparasitic agents. Genetic studies of 
prokaryotic PKS and NRPS produced detailed information 
regarding the function and the organization of genes respon 
sible for the biosynthesis of polyketides and nonribosomal 
peptides. Such knoWledge, in turn, made it possible to pro 
duce combinations of PKS and NRPS genes from different 
microorganisms in order to produce novel antibiotics 
(McDaniel et al., 1999; Rodriguez and McDaniel, 2001 ; Pfei 
fer et al., 2001). Investigating the complete albicidin biosyn 
thesis apparatus is therefore of great interest because such 
results may contribute to the knoWledge as to hoW PKS and 
NRPS interact and hoW they might be manipulated to engi 
neer novel molecules. 
A second study With X albilineans strain Xa23R1 from 
Florida revealed that at least tWo gene clusters, one spanning 
more than 48 kb, are involved in albicidin production (Rott et 
al., 1996). This conclusion Was based on the folloWing data: 
(I) ?fty Xa23R1 mutants defective in albicidin production 
Were isolated; (ii) a Xa23R1 genomic library of 845 clones, 
designated pALBl to pALB845, Was constructed; (iii) tWo 
overlapping DNA inserts of approximately 47 kb and 41 kb, 
from clones pALB540 and pALB571 respectively, comple 
mented forty-?ve mutants and Were supposed to contain a 
major gene cluster involved in albicidin production; (iv) a 
DNA insert of approximately 36 kb, from clone pALB639, 
complemented four of the ?ve remaining mutants not 
complemented by pALB540 and pALB571, and Was sup 
posed to contain a second region involved in albicidin pro 
US 7,510,852 B2 
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duction; and (V) the remaining mutant, AM37, Which Was not 
complemented by any of the three cosmids pALB540, 
pALB571 and pALB639, Was supposed to be mutated in a 
third region of the genome involved in albicidin production. 
The DNA sequences of all of the genes required to produce 
the albicidin family of polyketide antibiotics, the expressed 
protein amino acid sequences of all of the genes, and the 
deduced structure of Albicidin have not been previously 
reported, although fragmentary sequences that include three 
of the bio synthetic genes have been reported. Identi?cation of 
one albicidin gene, xabC, as a methyltransferase gene 
involved in albicidin biosynthesis is reported by Huang, G., 
Zhang, L. & Birch, R. G. (2000a, Gene 255, 327-333) and 
claimed as biologically active in producing a polyketide anti 
biotic in PCT WO 02/24736 A1. Identi?cation of a second 
albicidin gene, xabA, as a phosphopantetheinyl transferase 
gene is reported by Huang, G., Zhang, L. and Birch, R. G. 
(2000b) Gene 258, 193-199 and claimed as biologically 
active in producing a polyketide antibiotic in PCT WO 
02/24736 A1. Huang, G., Zhang, L. & Birch, R. G. (2001) 
Microbiology 147, 631-642, report a DNA sequence of xabB 
(GenBank accession # AF239749), a multi functional 
polyketide-peptide synthetase that may be essential for albi 
cidin biosynthesis in Xanlhomonas albilineans. This xabB 
gene is reported as full length by Birch in PCT W0 02/ 24736 
A1 (their seq. ID #1) and claimed by Birch in PCT WO 
02/24736 A1 as a biologically active polyketide synthase of 
4,801 amino acids in length, enabling production of albicidin. 
HoWever, the DNA sequence reported by Huang et al. (2001) 
in GenBank AF239749 and by Birch in PCT WO 02/24736 
A1 (their seq. ID #1) appears to be incomplete and missing 
6,234 bp of DNA sequence encoding 2,078 amino acids. The 
subject invention provides the complete DNA sequence of 
xabB (albI, our seq. 20) as 20,637 bp, encoding a biologically 
active polyketide synthase of 6,879 amino acids of in this 
application (our seq ID #26). Factors affecting biosynthesis 
by Xanlhomonas albilineans of albicidins antibiotics and 
phytotoxins are discussed in J. Appl. Microbiol. 85, 1023 
1028. and Wall, M. K. & Birch, R. G. (1997). Genes for 
albicidin biosynthesis and resistance span at least 69 kb in the 
genome of Xanlhomonas albilineans. Lett. Appl. Microbiol. 
24, 256-260. A gene from X albilineans strain Xa13, 
designed AlbF, Which confers high level albicidin resistance 
in Escherichia coli and Which encodes a putative albicidin 
ef?ux pump, Was directly submitted to Genbank by Bostock 
and Birch (Accession No. AF403709). 
SUMMARY OF THE INVENTION 
The present invention describes and characteriZes the fam 
ily of antibiotics that is produced by culturing chlorosis 
inducing strains of X albilineans and mutants thereof, 
together With the complete set of tWenty biosynthetic genes 
capable of producing the unique and previously uncharacter 
iZed family of antibiotics produced by X albilineans and 
previously lumped together as “albicidins.” The set of tWenty 
biosynthetic genes isolated, puri?ed and cloned from a cul 
ture of X albilineans revealed that this set of biosynthetic 
genes is capable of synthesiZing products exhibiting a high 
level of variation among the products, indicating that albici 
dins comprise a family of polyketide antibiotics. The albici 
dins described in the present invention are synthesiZed by 
tWenty genes, including one polyketide-peptide synthase, one 
polyketide synthase and tWo peptide synthases, but the sub 
strates of the polyketide-peptide synthase and of one peptide 
synthase are not ot-amino acids. The biosynthetic enzymes 
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represent a previously undescribed and unique polyketide 
antibiotic biosynthetic system. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a Physical Map and genetic organization of the 
DNA Region containing the major gene cluster XALBl 
involved in the biosynthesis of Albicidins. 
FIG. 2 is an illustration of the organiZation of the four PKS 
modules and the seven NRPS modules identi?ed in cluster 
XALBl and comparison With the organiZation of the prior art 
material XabB. 
FIG. 3 shoWs the conserved sequence motifs in O-methyl 
transferases and C-methyltransferases involved in antibiotic 
biosynthesis in bacteria and in AlbII. 
FIG. 4 shoWs the conserved sequence motifs in O-methyl 
transferases and in different tcmP-like hypothetical proteins 
and AlbVI. 
FIG. 5 is an illustration of the alignment of the primary 
sequences betWeen the conserved motifs A4 and A5 of Alb 
NPRSs and PKS-4 in Xanlhomonas albilineans With the cor 
responding sequences of GrsA (Phe) accession number: 
P14687 SEQ ID NO: 132 and Blm NRPS-2 ([3-Ala) accession 
number AF210249 (SEQ ID NO: 133); AlbI NRPS-1 (SEQ 
ID NO: 134); AlbI NRPS-3 (SEQ ID NO: 135); AlbIX 
NRPS-6 (SEQ ID NO: 136); AlbIX NRPS-7 (SEQ ID NO: 
137); AlbIV NRPS-5 (SEQ ID NO: 138); AlbVII PKS-4 
(SEQ ID NO: 139); AlbI NRPS-2 (SEQ ID NO: 140). 
FIG. 6 shoWs Rho-independent transcription ter'minators 
identi?ed in the intergenic regions of XALBl and XALB3 
clusters (SEQ ID NO: 141, XALBl Strand+(29 bp doWn 
stream from the TGA stop codon of albXVII); SEQ ID NO: 
142, XALBl Strand+(400 bp doWnstream from the TAA stop 
codon of albIV); SEQ ID NOs: 143, 144 and 145, XALBl 
Strand-(62 bp, 170 bp and 560 bp doWnstream from the TAG 
stop codon of albXVI); SEQ ID NOs: 146 and 147, XLAB3 
Strand+). 
FIG. 7A shoWs sequences identi?ed as a putative bidirec 
tional promoter betWeen albX and albXVII in XALBl for 
transcriptional control of operons 3 and 4 (SEQ ID NOs: 148 
and 149). 
FIG. 7B shoWs sequences identi?ed as a putative unidirec 
tional promoter upstream from albXIX for transcriptional 
control of operon 5 if albXVIII is not expressed (SEQ ID 
NOs: 152 and 153). 
FIG. 8 is a physical map and genetic organiZation of the 
DNA region containing the gene clusters XALB2 and 
XALB3 involved in albicidin production. 
FIG. 9A is linear model 1 leading to the biosynthesis of 
only one polyketide-polypeptide albicidin backbone. 
FIG. 9B is linear model 2 leading to the biosynthesis of 
four different polyketide-polypeptide backbone. 
FIG. 10A is an alignment of the conserved motifs in AT 
domains from RifA-1 (SEQ ID NO: 156), -2(SEQ ID NO: 
157), -3 (SEQ ID NO: 158), RifB-l (SEQ ID NO: 159), 
RitE-1 (SEQ ID NO: 160) (Rifamycin PKSs, August et al., 
1998) and BlmVIII (Bleomycin PKS; Du et al., 2000) (SEQ 
ID NO: 161). 
FIG. 10B is a comparison ofAlbXIII (SEQ ID NO: 162), 
FenF (a malonyl-CoA transacylase located upstream from 
mycA, Duitman et al., 1999) (SEQ ID NO: 163) and LipA (a 
lipase; ValdeZ et al., 1999) (SEQ ID NO: 164). 
FIG. 11A is a proposed model for biosynthesis of albicidin, 
including putative substrates of PKS and NRPS modules. 
FIG. 11B shoWs the proposed compositions and structures 
of albicidins. 
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FIG. 12 illustrates subcloning of operons 3 and 4 (from 
pALB540), XALB2 (from pAC389.1) and XALB3 (from 
pEV639) into a single plasmid, pOp3-4/XALB2-3. A 
BamHI-PstI fragment from pALB540, corresponding to a 
portion of operon 4, Was subcloned into pBCKS(+), yielding 
pBC/Op4D (step 1). A XhoI site Was introduced into this 
vector immediately upstream from the BfrI site by directed 
mutagenesis, yielding pBC/Op4DXhoI (step 2). The EcoRI 
fragment from pAC389.1 @(ALB2) Was then subcloned into 
pBC/Op4DXhoI, yielding pBC/Op4D/XALB2 (step 3). A 
BfrI fragment from pALB540 containing complete operon 3 
and the beginning of operon 4 Was subcloned into pBC/ 
Op4D/XALB2, yielding pBC/Op3-4/XALB2 (step 4). The 
SalI fragment from pEV639 @(ALB3) Was subcloned into 
pBKS, yielding pBKS/XALB3 (step 5). The SalI site located 
on the KpnI side of the polylinker Was then destroyed and 
substituted by a XhoI restriction site, yielding pBKS/ 
XALB3XhoI (step 6). Finally, the XhoI cassette of pBC/Op3 
4/XALB2 Was subcloned into the SalI restriction site of 
pBKS/XALB3XhoI, yielding pBKS/Op3-4/XALB2-3 (step 
7). An XhoI site Was added to the BamHI site of pLAFR3, 
yielding pLAFR3XhoI (step 8). The XhoI cassette from 
pBKS/Op3-4/XALB2-3 Was then cloned into pLAFR3XhoI, 
yielding pOp3-4/XALB2-3 (step 9). 
DETAILED DESCRIPTION OF THE INVENTION 
The invention results from the DNA sequencing of the 
complete major gene cluster XALBl, as Well as the noncon 
tiguous fragments XALB2 and XALB3.XALB1 is present in 
the tWo overlapping DNA inserts of clones pALB540 and 
pALB57l. Reading frame analysis and homology analyses 
alloW one to predict the genetic organiZation of XALBl and 
to assign a function to the genes potentially required for 
albicidin production. Based on the alignment of the different 
PKS and/ or NRPS enZymes encoded by XALBl We proposed 
a model for the albicidin backbone bio synthesis. HoWever the 
invention disclosed herein does not depend upon the accuracy 
of the proposed model. The invention includes the successful 
cloning and DNA sequencing of the second region of the 
genome (XALB2) involved in albicidin production and 
mutated in mutant AM37. 
The invention includes the characterization of the third 
region of the genome (XALB3) involved in albicidin produc 
tion present in clone pALB639. These results alloWed the 
possibility to characterize all enZymes of the albicidin bio 
synthesis pathWay including structural, resistance and regu 
latory elements and to engineer overproduction of albicidin. 
The subject invention provides: 
(a) isolated, recombinant, and/or puri?ed polynucleotide 
sequences comprising a polynucleotide sequence 
selected from the group consisting of SEQ ID NO: 1, 2, 
3,4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 
21, 22, 23, 24, and 25; 
(b) isolated, recombinant, and/or puri?ed polynucleotide 
sequences comprising a polynucleotide encoding a 
polypeptide selected from the group consisting of SEQ 
ID NO: 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 
39, 40, 41, 42, 43, 44, 45, 46, and 47; 
(c) isolated, recombinant, and/or puri?ed polynucleotide 
sequences comprising a polynucleotide that is comple 
mentary to a polynucleotide selected from the group 
consisting of1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 
16, 17, 18, 19, 20, 21, 22, 23, 24, and 25; 
(d) isolated, recombinant, and/or puri?ed polynucleotide 
sequences comprising a polynucleotide that is comple 
mentary to a polynucleotide encoding a polypeptide 
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selected from the group consisting of SEQ ID NO: 26, 
27; 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 
42, 43, 44, 45, 46, and 47; or 
(e) isolated, recombinant, and/or puri?ed polynucleotide 
sequences comprising a polynucleotide that is at least 
70% homologous to: (1) a polynucleotide selected from 
the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 
9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24, 
and 25; (2) a polynucleotide sequence encoding a 
polypeptide selected from the group consisting of SEQ 
ID NO: 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 
39, 40,41, 42, 43,44, 45, 46, and 47; (3) a polynucle 
otide that is complementary to a polynucleotide encod 
ing a polypeptide selected from the group consisting of 
SEQ ID NO: 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 
38, 39, 40, 41, 42, 43, 44, 45, 46, and 47; (3) a poly 
nucleotide that is complementary to a polynucleotide 
sequence selected from the group consisting of SEQ ID 
NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 
18, 19, 20, 21, 22, 23, 24, and 25; 
(f) isolated, recombinant, and/or puri?ed polynucleotide 
sequences comprising a polynucleotide sequence 
encoding variant (e.g., a variant polypeptide) of a 
polypeptide selected from the group consisting of SEQ 
ID NOs: 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 
39, 40, 41, 42, 43, 44, 45, 46, and 47, Wherein said 
variant has at least on of the biological activities associ 
ated With the polypeptides of SEQ ID NOs: 26, 27, 28, 
29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 
44, 45, 46, and 47; 
g) isolated, recombinant, and/or puri?ed polynucleotide 
sequences comprising polynucleotide sequence encod 
ing a fragment of a polypeptide selected from the group 
consisting ofSEQ ID NOs: 26, 27, 28, 29, 30, 31, 32, 33, 
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, and 47 
or a fragment of a variant polypeptide of SEQ ID NOs: 
26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 
41, 42, 43, 44, 45, 46, and 47; 
h) isolated, recombinant, and/or puri?ed polynucleotide 
sequences comprising a polynucleotide sequence 
encoding multimeric construct; 
j) a genetic construct comprising a polynucleotide 
sequence as set forth in (a), (b), (c), (d), (e), (f), (g), or 
(11); 
k) a vector comprising a polynucleotide sequence as set 
fOITh in (a), (b), (C), (d), (e), (f), (g), OM11); 
l) a host cell comprising a vector a polynucleotide sequence 
as set forth in (a), (b), (c), (d), (e), (f), (g), or (h); 
m) a transformed plant cell comprising a vector comprising 
a polynucleotide sequence as set forth in (a), (b), (c), (d), 
(e), (f), (g), Or (11); 
n) a transformed plant comprising a vector comprising a 
polynucleotide sequence as set forth in (a), (b), (c), (d), 
(e), (f), (g), Or (11); 0r; 
o) a polynucleotide that hybridiZes under loW, intermediate 
or high stringency With a polynucleotide sequence as set 
fOITh in (a), (b), (C), (d), (e), (f), (g), Or (11) 
“Nucleotide sequence”, “polynucleotide” or “nucleic 
acid” can be used interchangeably and are understood to 
mean, according to the present invention, either a double 
stranded DNA, a single-stranded DNA or products of tran 
scription of the said DNAs (e.g., RNA molecules). It should 
also be understood that the present invention does not relate to 
genomic polynucleotide sequences in their natural environ 
ment or natural state. The nucleic acid, polynucleotide, or 
nucleotide sequences of the invention canbe isolated, puri?ed 
(or partially puri?ed), by separation methods including, but 
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not limited to, ion-exchange chromatography, molecular size 
exclusion chromatography, or by genetic engineering meth 
ods such as ampli?cation, subtractive hybridization, cloning, 
subcloning or chemical synthesis, or combinations of these 
genetic engineering methods. 
A homologous polynucleotide or polypeptide sequence, 
for the purposes of the present invention, encompasses a 
sequence having a percentage identity With the polynucle 
otide orpolypeptide sequences, set forth herein, of betWeen at 
least (or at least about) 70.00% to 99.99% (inclusive). The 
aforementioned range of percent identity is to be taken as 
including, and providing Written description and support for, 
any fractional percentage, in intervals of 0.01%, betWeen 
20.00% and, up to, including 99.99%. These percentages are 
purely statistical and differences betWeen tWo nucleic acid 
sequences can be distributed randomly and over the entire 
sequence length. For example, homologous sequences can 
exhibit a percent identity of70, 71, 72, 73, 74, 75, 76, 77, 78, 
79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 
96, 97, 98, or 99 percent With the sequences of the instant 
invention. Typically, the percent identity is calculated With 
reference to the polynucleotide of a particular SEQ ID NO.; 
the full-length of a selected polynucleotide, or the native 
(naturally occurring) polynucleotide. The terms “identical” 
orpercent “identity”, in the context of tWo or more polynucle 
otide or polypeptide sequences, refer to tWo or more 
sequences or subsequences that are the same or have a speci 
?ed percentage of amino acid residues that are the same, 
When compared and aligned for maximum correspondence 
over a comparison WindoW, as measured using a sequence 
comparison algorithm or by manual alignment and visual 
inspection. 
A “complementary” polynucleotide sequence, as used 
herein, generally refers to a sequence arising from the hydro 
gen bonding betWeen a particular purine and a particular 
pyrimidine in double-stranded nucleic acid molecules (DNA 
DNA, DNA-RNA, or RNA-RNA). The major speci?c pair 
ings are guanine With cytosine and adenine With thymine or 
uracil. A “complementary” polynucleotide sequence may 
also be referred to as an “antisense” polynucleotide sequence 
or an “antisense” sequence. 
Sequence homology and sequence identity can also be 
determined by hybridization studies under high stringency, 
intermediate stringency, and/or loW stringency. Various 
degrees of stringency of hybridization can be employed. The 
more severe the conditions, the greater the complementarity 
that is required for duplex formation. Severity of conditions 
can be controlled by temperature, probe concentration, probe 
length, ionic strength, time, and the like. Preferably, hybrid 
ization is conducted under loW, intermediate, or high strin 
gency conditions by techniques Well knoWn in the art, as 
described, for example, in Keller, G. H., M. M. Manak [1987] 
DNA Probes, Stockton Press, NeW York, N.Y., pp. 169-170. 
It is also Well knoWn in the art that restriction enzymes can 
be used to obtain functional fragments of the subject DNA 
sequences. For example, Bal31 exonuclease can be conve 
niently used for time-controlled limited digestion of DNA 
(commonly referred to as “erase-a-base” procedures). See, 
for example, Maniatis et al. [1982] Molecular Cloning: A 
Laboratory Manual, Cold Spring Harbor Laboratory, NeW 
York; Wei et al. [1983] J. Biol. Chem. 258:13006-13512. 
The present invention further comprises fragments of the 
polynucleotide sequences of the instant invention. Represen 
tative fragments of the polynucleotide sequences according to 
the invention Will be understood to mean any nucleotide 
fragment having at least 5 successive nucleotides, preferably 
at least 12 successive nucleotides, and still more preferably at 
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least 15 or at least 20 successive nucleotides of the sequence 
from Which it is derived. The upper limit for such fragments 
is the total number of nucleotides found in the full-length 
sequence encoding a particular polypeptide (e.g., a polypep 
tide selected from the group consisting of SEQ ID NOs: 
26-50). The term “successive” can be interchanged With the 
term “consecutive”. In some embodiments, a polynucleotide 
fragment may be referred to as “a contiguous span of at least 
X nucleotides, Wherein X is any integer value beginning With 
5. The upper limit for polynucleotide fragments of the subject 
invention is the total number of nucleotides found in the 
full-length sequence of a particular SEQ ID or the total num 
ber of nucleotides encoding a particular polypeptide (e.g., a 
particular SEQ ID NO). 
In some embodiments, the subject invention includes those 
fragments capable of hybridizing under various conditions of 
stringency conditions (e.g., high or intermediate or loW strin 
gency) With a nucleotide sequence according to the invention; 
fragments that hybridize With a nucleotide sequence of the 
subject invention can be, optionally, labeled as set forth 
beloW. 
Thus, the subject invention also provides detection probes 
(e.g., fragments of the disclosed polynucleotide sequences) 
for hybridization With a target sequence or the amplicon 
generated from the target sequence. Such a detection probe 
Will comprise a contiguous/consecutive span of at least 8, 9, 
10, 11, 12, 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, 26, 27, 28, 
29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 
nucleotides. Labeled probes or primers are labeled With a 
radioactive compound or With another type of label as set 
forth above. Alternatively, non-labeled nucleotide sequences 
may be used directly as probes or primers; however, the 
sequences are generally labeled With a radioactive element 
(32P, 35S, 3H, 1251) or With a molecule such as biotin, acety 
lamino?uorene, digoxigenin, 5-bromo-deoxyuridine, or 
?uorescein to provide probes that can be used in numerous 
applications. 
The subject invention also provides for modi?ed nucle 
otide sequences. Modi?ed nucleic acid sequences Will be 
understood to mean any nucleotide sequence that has been 
modi?ed, according to techniques Well knoWn to persons 
skilled in the art, and exhibiting modi?cations in relation to 
the native, naturally occurring nucleotide sequences. 
The subject invention also provides genetic constructs 
comprising: a) a polynucleotide sequence encoding a 
polypeptide sequence selected from the group consisting of 
SEQ ID NOs: 1-25; b) a polynucleotide sequence having at 
least about 70% to 99.99% identity to a polynucleotide 
sequence encoding a polypeptide sequence selected from the 
group consisting of SEQ ID NO: 26-50, Wherein said poly 
nucleotide encodes a polypeptide having at least one of the 
biological activities of the polypeptides (e.g., a catalytic 
activity as set forth in Table 4); c) a polynucleotide sequence 
encoding a biologically active fragment of a polypeptide 
selected from the group consisting of SEQ ID NO: 26-50, 
Wherein said biologically active fragment has at least one of 
the biological activities of the polypeptides (e.g., a catalytic 
or transport activity as set forth in Table 4); d) a polynucle 
otide sequence comprising SEQ ID NO: 1, 2, 3, or combina 
tions thereof; e) a polynucleotide sequence encoding variant 
(e.g., a variant polypeptide) of a polypeptide selected from 
the group consisting of SEQ ID NOs: 2648, Wherein said 
variant has at least on of the biological activities associated 
With the polypeptides (e. g., a catalytic or transport activity as 
set forth in Table 4); f) a polynucleotide sequence encoding a 
fragment of a variant polypeptide as set forth in (e); or g) a 
polynucleotide sequence encoding multimeric construct. 
US 7,510,852 B2 
Genetic constructs of the subject invention can also contain 
additional regulatory elements such as promoters and 
enhancers and, optionally, selectable markers. 
Also Within the scope of the subject instant invention are 
vectors or expression cassettes containing polynucleotides 
encoding the polypeptides, set forth supra, operably linked to 
regulatory elements. The vectors and expression cassettes 
may contain additional transcriptional control sequences as 
Well. The vectors and expression cassettes may further com 
prise selectable markers. The expression cassette may contain 
at least one additional gene, operably linked to control ele 
ments, to be co-transformed into the organism. Alternatively, 
the additional gene(s) and control element(s) can be provided 
on multiple expression cassettes. Such expression cassettes 
are provided With a plurality of restriction sites for insertion 
of the sequences of the invention to be under the transcrip 
tional regulation of the regulatory regions. The expression 
cassette(s) may additionally contain selectable marker genes 
operably linked to control elements. 
In some embodiments, the expression cassette Will include 
in the 5'-3' direction of transcription, a transcriptional and 
translational initiation region, a DNA sequence of the inven 
tion, and a transcriptional and translational termination 
region functional in plants. The transcriptional initiation 
region, the promoter, may be native or analogous, or foreign 
or heterologous, to the plant host. Additionally, the promoter 
may be the natural sequence or alternatively a synthetic 
sequence. By “foreign” is intended that the transcriptional 
initiation region is not found in the native plant into Which the 
transcriptional initiation region is introduced. As used herein, 
a chimeric gene comprises a coding sequence operably linked 
to a transcriptional initiation region that is heterologous to the 
coding sequence. 
The termination region may be native With the transcrip 
tional initiation region, may be native With the operably 
linked DNA sequence of interest, or may be derived from 
another source. Convenient termination regions are available 
from the Ti-plasmid of A. Zumefaciens, such as the octopine 
synthase and nopaline synthase termination regions. See also 
Guerineau et al. (1991) Mol. Gen. Genet. 2621141-144; 
Proudfoot (1991) Cell 641671-674; Sanfacon et al. (1991) 
Genes Dev. 51141-149; Mogen et al. (1990) Plant Cell 
211261-1272; Munroe et al. (1990) Gene 911151-158; Ballas 
et al. (1989) Nucleic Acids Res. 1717891-7903; and Joshi et 
al. (1987) Nucleic Acid Res. 1519627-9639. 
Where appropriate, the polynucleotides encoding the 
polypeptides set forth supra can be optimiZed for expression 
in the transformed plant That is, the genes can be synthesiZed 
using plant-preferred codons corresponding to the plant of 
interest Methods are available in the art for synthesizing 
plant-preferred genes. See, for example, US. Pat. Nos. 5,380, 
831 and 5,436,391, and Murray et al. (1989) Nucleic Acids 
Res. 171477-498, herein incorporated by reference. 
The expression cassettes may additionally contain 5' leader 
sequences in the expression cassette construct. Such leader 
sequences can act to enhance translation. Translation leaders 
are knoWn in the art and include: picornavirus leaders, for 
example, EMCV leader (Encephalomyocarditis 5' noncoding 
region), Elroy-Stein et al. (1989) PNAS USA 8616126-6130; 
potyvirus leaders, for example, TEV leader (Tobacco Etch 
Virus), Allison et al. (1986); MDMV Leader (MaiZe DWarf 
Mosaic Virus), Virology 15419-20; human immunoglobulin 
heavy-chain binding protein (BiP), Macejak et al. (1991) 
Nature 353190-94; untranslated leader from the coat protein 
mRNA of alfalfa mosaic virus (AMV RNA 4), Jobling et al. 
(1987) Nature 3251622-625; tobacco mosaic virus leader 
(TMV), Gallie et al. (1989) in Molecular Biology of RNA, ed. 
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Cech (Liss, NeW York), pp. 237-256; and maiZe chlorotic 
mottle virus leader (MCMV), Lommel et al. (1 991) Virology 
811382-385. See also, Della-Cioppa et al. (1987) Plant 
Physiol. 841965-968. Other methods knoWn to enhance trans 
lation can also be utiliZed. 
Also provided are transformed host cells, transformed 
plant cells and transgenic plants Which contain one or more 
genetic constructs, vectors, or expression cassettes compris 
ing polynucleotides of the subject invention, or biologically 
active fragments thereof, operably linked to control elements. 
As used herein, the term “planta” includes algae and higher 
plants. Thus, algae, monocots, and dicots may be transformed 
With genetic constructs of the invention, expression cassettes, 
or vectors according to the invention. In certain embodiments 
of the subject invention, the transformed cells or transgenic 
plants comprise at least one polynucleotide sequence selected 
from the group consisting of SEQ ID NOs: 1-25. In certain 
preferred embodiments, transformed cells or transgenic 
plants comprise at least one polynucleotide sequence com 
prising SEQ ID NOs: 1, 2, or 3. Optionally, the transformed 
cells or transgenic plants can comprise at least tWo or all three 
polynucleotide sequences selected from the group consisting 
ofSEQ ID NOs: 1, 2, and 3. 
Methods of transforming cells With genetic constructs, 
vectors, or expression cassettes comprising the novel poly 
nucleotides of the invention are also provided. These methods 
comprise transforming a plant or plant cell With a polynucle 
otide according to the subject invention. Plants and plant cells 
may be transformed by electroporation, Agrobacterium trans 
formation (including vacuum in?ltration), engineered plant 
virus replicons, electrophoresis, microinjection, micro-pro 
jectile bombardment, vacuum in?ltration of Agrobacterium, 
micro-LASER beam-induced perforation of cell Wall, or sim 
ply by incubation With or Without polyethylene glycol (PEG). 
Plants transformed With a genetic construct of the invention 
may be produced by standard techniques knoWn in the art for 
the genetic manipulation of plants. DNA can be transformed 
into plant cells using any suitable technology, such as a dis 
armed Ti-plasmid vector carried by A grobaclerium exploit 
ing its natural gene transferability. Agrobacterium transfor 
mation is used by those skilled in the art to transform algae 
and dicotyledonous species. Substantial progress has been 
made toWards the routine production of stable, fertile trans 
genic plants in almost all economically relevant monocot 
plants. In particular, A grobaclerium mediated transformation 
has noW emerged as a highly e?icient transformation method 
in monocots. Microproj ectile bombardment, electroporation, 
and direct DNA uptake are preferred Where A grobacleri um is 
inef?cient or ineffective. Alternatively, a combination of dif 
ferent techniques may be employed to enhance the ef?ciency 
of the transformation process, e. g., bombardment With Agro 
bacterium-coated microparticles (EP-A486234) or micro 
projectile bombardment to induce Wounding folloWed by co 
cultivation With A grobaclerium (EP-A-486233). 
Following transformation, a plant may be regenerated, e. g., 
from single cells, callus tissue or leaf discs, as is standard in 
the art. Almost any plant can be entirely regenerated from 
cells, tissues, and organs of the plant. Available techniques are 
revieWed in Vasil et al. (1984) in Cell Culture and Somatic 
Cell Genetics of Plants, Vols. I, II, and II, Laboratory Proce 
dures and Their Applications (Academic press); and Weiss 
bach et al. (1989) Methods for Plant Mol. Biol. 
The transformed plants may then be groWn, and either 
pollinated With the same transformed strain or different 
strains, and the resulting hybrid having expression of the 
desired phenotypic characteristic identi?ed. TWo or more 
generations may be groWn to ensure that expression of the 


































































































































